CLN: Recent Downgrade And Trimmed Assumptions Will Shape Potential Upside

Analysts have trimmed their CHF price targets for Clariant by a small amount, reflecting more cautious assumptions on revenue growth and profit margins. They are still applying a slightly higher future P/E multiple in their updated models.

Analyst Commentary

Recent Street research on Clariant points to a mixed stance, with some analysts turning more cautious while still fine tuning their valuation frameworks rather than making wholesale changes.

Bullish Takeaways

Bullish analysts continue to use earnings based valuation, with a slightly higher future P/E multiple indicating some confidence that the shares could warrant a premium if execution on revenue and margins holds up.
The limited size of recent price target adjustments suggests that, for optimistic analysts, the core long term thesis on Clariant remains largely intact rather than being fundamentally rewritten.
Maintaining Hold level stances rather than moving to more negative ratings signals that, for now, bullish analysts see the current valuation as broadly aligned with expected execution risks.

Bearish Takeaways

Goldman Sachs has downgraded Clariant, which signals that at least one major firm now sees a weaker risk reward trade off at the current share price.
Bearish analysts have trimmed CHF price targets, including a move to CHF 7.80 from CHF 8, reflecting more cautious assumptions on revenue growth and profit margins.
The combination of lower price targets and more cautious ratings indicates concern that execution on profitability may fall short of earlier expectations.
For more cautious analysts, the use of a higher future P/E multiple alongside lower targets suggests the starting point for earnings may be the key concern, rather than the valuation framework itself.

What's in the News

Clear Street is considering reducing both the size and price range of its IPO, with a potential move from 23.8m shares at US$40 to US$44 to 13m shares at US$26 to US$28, which would imply proceeds of about US$364m and a valuation of about US$7.2b if the share count is reduced in line with the offer size (Bloomberg).
The possible IPO adjustment at Clear Street highlights how primary equity markets can remain sensitive to pricing and deal size. This is relevant context if you are comparing capital market conditions across companies, including Clariant, when thinking about funding flexibility or equity issuance risk (Bloomberg).

Valuation Changes

Fair Value: CHF 8.98 to CHF 8.93, a small reduction that keeps the implied upside or downside broadly similar to before.
Discount Rate: 5.80% to about 5.73%, a slight adjustment that moderately lowers the required return used in the updated model.
Revenue Growth: 1.38% to about 1.07%, a meaningful reduction in assumed CHF revenue growth that reflects a more cautious view on the top line.
Net Profit Margin: 6.97% to about 6.59%, a moderate cut to expected profitability that indicates a thinner cushion on earnings quality.
Future P/E: 12.32x to about 13.03x, a modest increase in the valuation multiple that partly offsets the lower earnings base in the new assumptions.

0 views

Key Takeaways

Expansion in China and a focus on specialty, sustainable chemicals position Clariant to benefit from growing local demand and regulatory trends.
Ongoing digitalization, efficiency measures, and a premium product portfolio underpin cost savings, resilient margins, and long-term earnings growth despite slow sales growth.
Lingering macroeconomic weaknesses, competitive threats, and increased structural costs may constrain Clariant's revenue growth, margin strength, and long-term earnings stability.

Catalysts

About Clariant

Develops, manufactures, distributes, and sells specialty chemicals in Switzerland, Europe, the Middle East, Africa, the United States, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

The ramp-up of two new plants in China for Care Chemicals and Additives will significantly increase local production, aligning with rising local content requirements and sustainability preferences in Asia-Pacific. This positions Clariant to better capture demand from the expanding middle class and mitigate tariff risks, supporting multi-year revenue growth and margin stability.
Clariant's ongoing performance improvement and digitalization initiatives, such as the CLARITY platform in Catalysts and footprint optimization, are driving substantial cost savings and operational efficiencies. These measures are expected to deliver CHF 80 million annual savings by 2027 and aid in reaching a targeted 40% free cash flow conversion, boosting EBITDA margins and bottom line growth.
The company's increasing reliance on specialty and sustainable chemical solutions, illustrated by innovations like soil-release polymers and Lucas Meyer Cosmetics' premium segment growth, directly targets rising regulatory and consumer demand for environmentally friendly, high-value products. This supports premium pricing and recurring revenues, driving net margin resilience.
Clariant's higher-value, less commoditized portfolio, together with structural cost reductions and value-over-volume strategy, has consistently increased EBITDA margins (from 14.6% in 2023 to a guided 17-18% in 2025) despite modest organic sales growth, indicating a robust foundation for future earnings growth even in slow economic conditions.
Strategic capital redeployment into innovation-driven, regulation-compliant businesses (post-divestment of pigments and masterbatches) positions Clariant at the forefront of secular trends such as sustainability and the clean energy transition, opening new revenue streams in bio-based chemicals, EV batteries, and sustainable agriculture, which is likely to positively impact revenues and return on invested capital over the long-term.

Clariant Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Clariant's revenue will grow by 1.1% annually over the next 3 years.
Analysts assume that profit margins will increase from -1.9% today to 6.6% in 3 years time.
Analysts expect earnings to reach CHF 266.5 million (and earnings per share of CHF 0.86) by about April 2029, up from -CHF 75.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CHF339.9 million in earnings, and the most bearish expecting CHF230.5 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 13.1x on those 2029 earnings, up from -34.2x today. This future PE is lower than the current PE for the GB Chemicals industry at 23.4x.
Analysts expect the number of shares outstanding to grow by 0.08% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.73%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent weak industrial production outlook and ongoing macroeconomic uncertainties, particularly with slowing industrial and chemical production growth forecasts globally, may constrain Clariant's top-line revenue growth for multiple years, limiting overall earnings potential.
Increased exposure to China amid tariffs, overcapacity, and muted demand-despite ramping up local manufacturing-could keep volumes and prices under pressure in a key growth region, negatively impacting revenue stability and margin resilience.
Heavy restructuring and footprint rationalization, while supporting margins in the near term, may reduce business diversification and make Clariant more vulnerable to cyclical downturns or sector-specific shocks, ultimately risking revenue concentration and increasing earnings volatility.
Intensifying competition-both from Asian low-cost producers (which may drive global margin compression) and European peers willing to cut prices to sustain volumes-threatens Clariant's ability to maintain premium pricing and differentiated EBITDA margins long term.
Rising compliance costs related to decarbonization targets, ongoing legal risks such as the Ethylene litigation, and fixed cost increases from restructuring activities may collectively exert downward pressure on net income, free cash flow, and long-term earnings quality.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF8.93 for Clariant based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF13.0, and the most bearish reporting a price target of just CHF5.7.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF4.0 billion, earnings will come to CHF266.5 million, and it would be trading on a PE ratio of 13.1x, assuming you use a discount rate of 5.7%.
Given the current share price of CHF7.8, the analyst price target of CHF8.93 is 12.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Clariant?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Earnings Recovery Will Depend On Stabilization And Cost Improvements Amid Headwinds